Beyond the thematic-Why ethical is not just another short term theme



Mike Murray
Australian Ethical

The Inside Network

Where does the ESG thematic fit?

Shades of green



ESG integration

The explicit inclusion of environmental, social and governance (ESG) factors into traditional financial analysis.

Portfolio screening

Does or does not invest in sectors, companies, practices or countries based on ESG or ethical criteria.

Corporate advocacy

Influences corporate behaviour through direct engagement and shareholder action

Sustainability themed

Focuses on investment in themes or assets specifically related to sustainability factors

Impact investing

Targeted investments aimed at solving social or environmental problems while delivering financial returns


ESG themed vs Ethical investment



State of the world

Passive ESG themed

- ESG risk/return
- Benchmark tracking



Investors

Active Ethical


- Inherent value of people, planet, animals
- Impact focus

Risk adjusted returns?

True to label impact?

Sector allocation vs the market







How do index ESG themed ETFs measure up in Australia?

| Sector Exposure: | ETF 1 | ETF 2 | ETF3 |
|----------------------------------------|-------|-------|------|
| Financials and Realestate | 38% | 33% | 53% |
| Healthcare | 23% | 12% | 9% |
| IT and Communications | 21% | 16% | 6% |
| Industrials and Materials | 12% | 35% | 21% |
| Consumer | 5% | 4% | 11% |
| Utilities and Energy | 0% | 0% | 1% |
| Total | 100% | 100% | 100% |
| | | | |
| Ethical Screening: | | | |
| % stocks screened out under AE Charter | ~15% | ~37% | ~39% |
| | | | |

^{*}as at 28 February 2022

^{**} estimated percentage of stock names screened out (not weights) basis

Performance of ESG ETFs in Australia




| Feb-22 | 3 mths | 1 yr | 3 yr | 5 yr |
|-----------------------------------------|--------|-------|-------|------|
| | | | | |
| Index Tracking Funds: | | | | |
| Product 1 | -9.1% | 9.0% | 7.3% | n/a |
| Product 2 | -6.1% | 11.1% | 7.8% | 6.8% |
| Product 3 | -2.9% | 12.2% | 6.1% | 6.0% |
| | | | | |
| ASX 300 | 2.0% | 10.3% | 8.7% | 8.6% |
| | | | | |
| Fundamental Active Strategies | | | | |
| Active ETF 1 (dual class managed Fund)* | -0.2% | 15.5% | 11.3% | 7.2% |
| Active ETF 2 (quoted managed Fund) | 0.6% | n/a | n/a | n/a |
| | | | | |

^{*}includes performance history of unquoted managed fund prior to ETF class listing

^{**} all funds are quoted net of fees

Passive pitfalls






^{*}The Australian Financial Review, April 6 2021: Kiwi energy players brace for BlackRock ETFs' mega selldown

The Inside Network

Thematic tailwinds and alpha

Healthcare

Financials



- Index unaware
- Fundamental valuations
- Patient providers of capital
- Portfolio resilience



Case study: Investing in Healthcare

1. Thematic tailwinds

- Ageing population
- Technological development
- Essential need and social good

2. Business Model characteristics


- Recurring, defensive earnings
- High margins
- Global scalability

3. Key Risk Factors

- Regulatory
- Product
- Animal testing (ethical)

Two decades of returns of the ASX 300 Healthcare Sector





- 2012-2021 CAGR
 - Healthcare 300: 20.8%
 - ASX 300: 10.8%
- 2002-2011 CAGR
 - Healthcare 300: 4.1%
 - ASX 300: 6.1%

Current positioning in Healthcare



Positioning for:

- Under-levered balance sheets
- COVID volume recovery plays
- Increased role of private health
- Intersection of health with technology
- Products over services
- Capital discipline

Ethical considerations:

- Animal testing
- Drug pricing

"When Merck set the price for its immunotherapy cancer drug Keytruda at **more than \$150,000** per year, doctors and patients were **alarmed**."*





Current healthcare exposure AEAE.CXA High Conviction Fund

Global Growth

Ansell Limited

Cochlear Limited

CSL Limited

Fisher & Paykel Healthcare

Nanosonics Limited

Pro Medicus Limited

Resmed

Sonic Healthcare Limited

Domestic Leaders

Australian Pharmaceutical Ind.

Estia Health Ltd.

Healius Limited

Integral Diagnostics Ltd.

Medibank Private Ltd.

NIB Holdings Ltd

Ramsay Health Care Limited

Sigma Healthcare Ltd

Virtus Health Ltd.

Biotech

Clinuvel Pharmaceuticals Limited

Immutep Ltd

Imugene Limited

Mayne Pharma Group Limited

Mesoblast Limited

Opthea Limited

Paradigm Bio. Ltd.

Polynovo Limited

Starpharma Holdings Limited

Telix Pharmaceuticals Ltd.

Global Growth Basket

Median 10 yr return pa.

Median PE:

Portfolio overweight

Domestic Leaders Basket

Median 10 yr perf

Median PE:

26.5%

Portfolio overweight -6.0%

Biotech Basket

| 12.8% | Median 10 yr perf | 10.9% |
|-------|----------------------|-------|
| 19.2 | Median PE: | n/a |
| 10.0% | Portfolio overweight | 0.3% |

^{*}Dec 21, medians exclude stocks with <10 yrs data

Disclaimer



Australian Ethical Investment Ltd (ABN 47 003 188 930; Australian Financial Services Licence No. 229949) is the Responsible Entity and Investment Manager of the Australian Ethical Managed Investment Funds. Interests in the Australian Ethical Retail Superannuation Fund (ABN 49 633 667 743; Fund Registration No. R1004731) are offered by Australian Ethical Investment Ltd by arrangement with its subsidiary and trustee of the Super Fund, Australian Ethical Superannuation Pty Ltd (ABN 43 079 259 733, Registerable Superannuation Entity Licence No. L0001441).

The information contained in this presentation is general information only, and does not take into account your individual investment objectives, financial situation or needs. Before acting on it, you should consider seeking independent financial advice that is tailored to suit your personal circumstances and should refer to the Financial Services Guide, Product Disclosure Statements and Additional Information Booklets available on our website (www.australianethical.com.au).

Certain statements in this presentation relate to the future. Such statements involve known and unknown risks and uncertainties and other important factors that could cause the actual results, performance or achievements to be materially different from expected future results. Australian Ethical Investment Ltd does not give any representation, assurance or guarantee that the events expressed or implied in any forward-looking statements in this update will actually occur and you are cautioned not to place undue reliance on such statements.

The content of this presentation is intended to provide a summary and general overview concerning matters of interest and is correct as at the date of publication. It has not been subject to auditor review. Australian Ethical Investment Ltd does not accept any liability, either directly or indirectly, arising from any person relying, either wholly or partially, upon any information shown in, or omitted from, this update. Under no circumstances will Australian Ethical Investment Ltd be liable for any loss or damage caused by your reliance on information obtained from this update. You should consider seeking independent advice from a legal or other professional adviser before acting in response to the content of this update.



Thank you!

Mike Murray

Australian Ethical

